Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas

Correlation with the prognostic factors

Young Sik Kim, Kwang Hee Kim, Jung Ah Choi, Ju Lee Han, Han Kyeom Kim, Nam Hee Won, Insun Kim

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background and Objective. - Fas ligand (Fast, CD95L) is a type II transmembrane protein of the tumor necrosis factor family that induces cells to send an apoptotic signal to cells expressing Fas (CD95, APO-1). It has been shown that cancers have a dysregulated expression of Fas and FasL system, conferring a survival advantage. It is important to understand FasL and Fas expression in tumors, because the growth of cancer might be controlled by Fas-mediated apoptosis. Methods. - The expressions of FasL and Fas were studied by immunohistochemical analyses in 51 cases of renal cell carcinomas and the adjacent normal renal tissues, respectively. In addition, their expressions were compared with prognostic factors, such as tumor size, nuclear grade, TNM stage, and histologic types. Results. - In nonneoplastic renal tissues, FasL was expressed in all nephron segments, whereas Fas also expressed in all tubules, except for glomeruli, in renal cell carcinomas, FasL protein was detected in 50 (98.0%) of 51 cases, whereas Fas expressed in 38 (74.5%) of 51 cases. In fact, the immunostaining of Fas was less intense than that in the adjacent normal segments of all cases. The staining pattern showing both high expression of FasL and low expression of Fas was found in 36 (70.6%) (P = .04) of 51 cases, most of which were Fuhrman grade 2 or 3 tumors. However, the expression pattern did not correlate statistically with the tumor size, histologic type, or clinical stage. On the other hand, most grade 4 tumors displayed high expression of both FasL and Fas (P < .001). Conclusion. - These data indicate that high expression of FasL and low expression of Fas protein in renal cell carcinomas may play a role in evading surveillance of the immune system. In addition, the FasL and Fas expressions appear to have a therapeutic implication for high-grade tumors rather than a prognostic one.

Original languageEnglish
Pages (from-to)687-693
Number of pages7
JournalArchives of Pathology and Laboratory Medicine
Volume124
Issue number5
Publication statusPublished - 2000 Jun 8

Fingerprint

Fas Ligand Protein
Renal Cell Carcinoma
Neoplasms
Kidney
Nephrons
Immune System
Proteins
Tumor Necrosis Factor-alpha
Apoptosis
Staining and Labeling
Growth

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas : Correlation with the prognostic factors. / Kim, Young Sik; Kim, Kwang Hee; Choi, Jung Ah; Lee Han, Ju; Kim, Han Kyeom; Won, Nam Hee; Kim, Insun.

In: Archives of Pathology and Laboratory Medicine, Vol. 124, No. 5, 08.06.2000, p. 687-693.

Research output: Contribution to journalArticle

@article{d049fd3b04c24989abc33fcfa475f92e,
title = "Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: Correlation with the prognostic factors",
abstract = "Background and Objective. - Fas ligand (Fast, CD95L) is a type II transmembrane protein of the tumor necrosis factor family that induces cells to send an apoptotic signal to cells expressing Fas (CD95, APO-1). It has been shown that cancers have a dysregulated expression of Fas and FasL system, conferring a survival advantage. It is important to understand FasL and Fas expression in tumors, because the growth of cancer might be controlled by Fas-mediated apoptosis. Methods. - The expressions of FasL and Fas were studied by immunohistochemical analyses in 51 cases of renal cell carcinomas and the adjacent normal renal tissues, respectively. In addition, their expressions were compared with prognostic factors, such as tumor size, nuclear grade, TNM stage, and histologic types. Results. - In nonneoplastic renal tissues, FasL was expressed in all nephron segments, whereas Fas also expressed in all tubules, except for glomeruli, in renal cell carcinomas, FasL protein was detected in 50 (98.0{\%}) of 51 cases, whereas Fas expressed in 38 (74.5{\%}) of 51 cases. In fact, the immunostaining of Fas was less intense than that in the adjacent normal segments of all cases. The staining pattern showing both high expression of FasL and low expression of Fas was found in 36 (70.6{\%}) (P = .04) of 51 cases, most of which were Fuhrman grade 2 or 3 tumors. However, the expression pattern did not correlate statistically with the tumor size, histologic type, or clinical stage. On the other hand, most grade 4 tumors displayed high expression of both FasL and Fas (P < .001). Conclusion. - These data indicate that high expression of FasL and low expression of Fas protein in renal cell carcinomas may play a role in evading surveillance of the immune system. In addition, the FasL and Fas expressions appear to have a therapeutic implication for high-grade tumors rather than a prognostic one.",
author = "Kim, {Young Sik} and Kim, {Kwang Hee} and Choi, {Jung Ah} and {Lee Han}, Ju and Kim, {Han Kyeom} and Won, {Nam Hee} and Insun Kim",
year = "2000",
month = "6",
day = "8",
language = "English",
volume = "124",
pages = "687--693",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "5",

}

TY - JOUR

T1 - Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas

T2 - Correlation with the prognostic factors

AU - Kim, Young Sik

AU - Kim, Kwang Hee

AU - Choi, Jung Ah

AU - Lee Han, Ju

AU - Kim, Han Kyeom

AU - Won, Nam Hee

AU - Kim, Insun

PY - 2000/6/8

Y1 - 2000/6/8

N2 - Background and Objective. - Fas ligand (Fast, CD95L) is a type II transmembrane protein of the tumor necrosis factor family that induces cells to send an apoptotic signal to cells expressing Fas (CD95, APO-1). It has been shown that cancers have a dysregulated expression of Fas and FasL system, conferring a survival advantage. It is important to understand FasL and Fas expression in tumors, because the growth of cancer might be controlled by Fas-mediated apoptosis. Methods. - The expressions of FasL and Fas were studied by immunohistochemical analyses in 51 cases of renal cell carcinomas and the adjacent normal renal tissues, respectively. In addition, their expressions were compared with prognostic factors, such as tumor size, nuclear grade, TNM stage, and histologic types. Results. - In nonneoplastic renal tissues, FasL was expressed in all nephron segments, whereas Fas also expressed in all tubules, except for glomeruli, in renal cell carcinomas, FasL protein was detected in 50 (98.0%) of 51 cases, whereas Fas expressed in 38 (74.5%) of 51 cases. In fact, the immunostaining of Fas was less intense than that in the adjacent normal segments of all cases. The staining pattern showing both high expression of FasL and low expression of Fas was found in 36 (70.6%) (P = .04) of 51 cases, most of which were Fuhrman grade 2 or 3 tumors. However, the expression pattern did not correlate statistically with the tumor size, histologic type, or clinical stage. On the other hand, most grade 4 tumors displayed high expression of both FasL and Fas (P < .001). Conclusion. - These data indicate that high expression of FasL and low expression of Fas protein in renal cell carcinomas may play a role in evading surveillance of the immune system. In addition, the FasL and Fas expressions appear to have a therapeutic implication for high-grade tumors rather than a prognostic one.

AB - Background and Objective. - Fas ligand (Fast, CD95L) is a type II transmembrane protein of the tumor necrosis factor family that induces cells to send an apoptotic signal to cells expressing Fas (CD95, APO-1). It has been shown that cancers have a dysregulated expression of Fas and FasL system, conferring a survival advantage. It is important to understand FasL and Fas expression in tumors, because the growth of cancer might be controlled by Fas-mediated apoptosis. Methods. - The expressions of FasL and Fas were studied by immunohistochemical analyses in 51 cases of renal cell carcinomas and the adjacent normal renal tissues, respectively. In addition, their expressions were compared with prognostic factors, such as tumor size, nuclear grade, TNM stage, and histologic types. Results. - In nonneoplastic renal tissues, FasL was expressed in all nephron segments, whereas Fas also expressed in all tubules, except for glomeruli, in renal cell carcinomas, FasL protein was detected in 50 (98.0%) of 51 cases, whereas Fas expressed in 38 (74.5%) of 51 cases. In fact, the immunostaining of Fas was less intense than that in the adjacent normal segments of all cases. The staining pattern showing both high expression of FasL and low expression of Fas was found in 36 (70.6%) (P = .04) of 51 cases, most of which were Fuhrman grade 2 or 3 tumors. However, the expression pattern did not correlate statistically with the tumor size, histologic type, or clinical stage. On the other hand, most grade 4 tumors displayed high expression of both FasL and Fas (P < .001). Conclusion. - These data indicate that high expression of FasL and low expression of Fas protein in renal cell carcinomas may play a role in evading surveillance of the immune system. In addition, the FasL and Fas expressions appear to have a therapeutic implication for high-grade tumors rather than a prognostic one.

UR - http://www.scopus.com/inward/record.url?scp=12944314964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944314964&partnerID=8YFLogxK

M3 - Article

VL - 124

SP - 687

EP - 693

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 5

ER -